Menu Search
Equities

Eden Research PLC

EDNSF:PKC

Eden Research PLC

Actions
  • Price (USD)0.05
  • Today's Change0.00 / 0.00%
  • Shares traded10.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 24 2024 14:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eden Research plc is a United Kingdom-based company, which is focused on biopesticides for sustainable agriculture. The Company develops and supplies biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Its products are formulated with terpene active ingredients, based on natural plant defense metabolites. Its product portfolio includes Mevalone and Cedroz. Mevalone is a foliar biofungicide, which targets a key disease affecting grapes and other high-value fruit and vegetable crops. Cedroz is a bionematicide that targets free-living nematodes, which are parasitic worms that affect a range of high-value fruit and vegetable crops globally. The Company's Sustaine encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease of use.

  • Revenue in GBP (TTM)3.94m
  • Net income in GBP-1.52m
  • Incorporated1995
  • Employees19.00
  • Location
    Eden Research PLC67C Innovation Drive, Milton ParkOXFORD OX14 4RQUnited KingdomGBR
  • Phone+44 128 535 9555
  • Fax+44 199 377 6480
  • Websitehttp://www.edenresearch.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.